Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | NPC1 | O15118 | 4/20 | 0.82 |
| ▸ | RAB9A | P51151 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.82 |
| ▸ | HPGD | P15428 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 3/20 | 0.82 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.82 |
| ▸ | CASP3 | P42574 | 1/20 | 0.82 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.82 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.82 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.82 |
| ▸ | EGFR | P00533 | 2/20 | 0.77 |
| ▸ | SRC | P12931 | 1/20 | 0.77 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.74 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3644507 | 1.00 | LCK (1.00) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31741263 | 0.91 | MAPT (1.00) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL311405 | 0.91 | MAPT (1.00) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31238426 | 0.85 | MAPT (0.94) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10305788 | 0.85 | CSNK2A2 (1.00) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| 6-Hydroxyflavone SCHEMBL676594 | 0.84 | MAPT (1.00) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| 6-Hydroxyflavone SCHEMBL29628861 | 0.84 | MAPT (1.00) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31238388 | 0.82 | MAPT (0.78) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL311326 | 0.82 | MAPT (0.78) | LCKMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29664594 | 0.82 | ALOX5 (0.78) | LCKMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20260128175-A1 | Methods and Systems for Analysis of Gene Expression Data | AMPEL BIOSOLUTIONS LLC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250078957-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250022541-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20250011886-A1 | Systems and Methods for Targeting COVID-19 Therapies | AMPEL BIOSOLUTIONS, LLC | 2025-01-09 | — | — | US | disclosed |
| US-20240428948-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4479973-A1 | UNSUPERVISED MACHINE LEARNING METHODS | Ampel Biosolutions, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3230319-B1 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | RINAT NEUROSCIENCE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220273585-A1 | Composition comprising at least one natural or synthetic non-euphoric cannabinoid and its method of manufacture | TILMAN (BE) | 2022-09-01 | — | — | US | disclosed |
| EP-4049654-A1 | COMPOSITION COMPRISING AT LEAST ONE NATURAL OR SYNTHETIC CANNABINOID WITHOUT EUPHORIC EFFECT AND MANUFACTURING METHOD THEREOF | Eleonor (BE) | 2022-08-31 | — | — | EP | disclosed |
| US-20220249657-A1 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | RINAT NEUROSCIENCE CORP. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-11338035-B2 | Anti-PD-1 antibodies and methods of use thereof | RINAT NEUROSCIENCE CORP. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3989943-A1 | COMPOSITION COMPRISING AT LEAST ONE TRITERPENE AND/OR AT LEAST ONE TRITERPENOID AND/OR AT LEAST ONE OF THE GLYCOSYLATED FORMS THEREOF | Tilman (BE) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022079090-A1 | COMPOSITION COMPRISING AT LEAST ONE LABDANE DITERPENE AND METHOD FOR MANUFACTURING SAME | TILMAN SA (BE) | 2022-04-21 | — | — | WO | disclosed |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273585-A1 | Composition comprising at least one natural or synthetic non-euphoric cannabinoid and its method of manufacture | CNR2, CNR1, FAAH | LCK 2651/4885MAPT 584/4885NPC1 219/4885 |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | HMGB3, HCCS, ACACA | LCK 2749/4885MAPT 4430/4885NPC1 107/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | LCK 4514/4885MAPT 4452/4885NPC1 3038/4885 |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | APP, PSEN1, BACE1 | LCK 3041/4885MAPT 9/4885NPC1 905/4885 |
| US-20260128175-A1 | Methods and Systems for Analysis of Gene Expression Data | IRAK4, TLR4, TLR2 | LCK 447/4885MAPT 3797/4885NPC1 3587/4885 |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | SSB, METTL16, TLR9 | LCK 3368/4885MAPT 4802/4885NPC1 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.